THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTI

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT

IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,

IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS

OF SUCH JURISDICTION

Tiziana Life Sciences plc

Result of Annual General Meeting

At the Annual General Meeting of the Company held

at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed.

proxy voting will be available shortly on the Company's website, https://ir.tizianalifesciences.com/shareholder-services/annual-general-meeting.

The Company also confirms that it has re-activated

its strategic plan to redomicile to Bermuda; shareholders will receive further information in due course.

The person who arranged for the release of this

announcement was Keeren Shah, Chief Financial Officer.

Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) is a UK biotechnology company that focuses on the discovery

and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib (a CDK inhibitor being

developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the

only second generation fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential

application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis,

multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response

is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for

treatment of IL6-induced inflammatory pulmonary diseases.

For further enquiries: